Elephas Biosciences Corporation, a US-based private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced on Thursday an exclusive partnership with India-based Neuberg Diagnostics, a pathology and molecular diagnostics group.

Under the agreement, Neuberg will become Elephas' commercial partner in India, marking a significant step in Elephas' global commercialisation strategy.

Elephas says that it continues to pursue strategic partnerships with international organisations that share its mission of improving outcomes for patients undergoing immunotherapy. Together with Elephas, Neuberg says that it will bring the elive platform into its own laboratory infrastructure, with the goal of launching its own clinical test in India by the end of 2026.

The partnership combines Neuberg's established oncology diagnostics expertise with Elephas' functional research platform. Pairing these complementary technologies is claimed to provide oncologists with a more comprehensive view of cancer by integrating molecular profiling with live tumour functional testing.

Alongside the commercial agreement, Neuberg will serve as Elephas' research partner in India, processing tumour biopsy samples on the elive platform at its flagship laboratory in Ahmedabad. This research is expected to generate local evidence supporting the platform's performance as it moves toward broader adoption.